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Susceptibility to tuberculosis is historically ascribed
to an inadequate immune response that fails to
control infecting mycobacteria. In zebrafish, we find
that susceptibility to Mycobacterium marinum can
result from either inadequate or excessive acute
inflammation.Modulation of the leukotriene A4 hydro-
lase (LTA4H) locus, which controls the balance of
pro- and anti-inflammatory eicosanoids, reveals two
distinct molecular routes to mycobacterial suscepti-
bility converging on dysregulated TNF levels: inade-
quate inflammationcausedbyexcess lipoxinsandhy-
perinflammation driven by excess leukotriene B4. We
identify therapies that specifically target each of these
extremes. In humans, we identify a single nucleotide
polymorphism in the LTA4H promoter that regulates
its transcriptional activity. In tuberculous meningitis,
the polymorphism is associated with inflammatory
cell recruitment, patient survival and response to
adjunctive anti-inflammatory therapy. Together, our
findings suggest that host-directed therapies tailored
to patient LTA4H genotypes may counter detrimental
effects of either extreme of inflammation.
INTRODUCTION
Susceptibility to tuberculosis (TB) is typically associated with
failed immunity. Genetic deficiencies of immune effectors in-
cluding Tumor Necrosis Factor (TNF) and interferon-<gamma>434 Cell 148, 434–446, February 3, 2012 ª2012 Elsevier Inc.confer increased susceptibility to mycobacterial disease (Fortin
et al., 2007). Similarly, a range of nongenetic immunosuppres-
sion—Human ImmunodeficiencyVirus (HIV) infection, TNF-block-
ing and glucocorticoid treatments—increases susceptibility to TB
(Kwan and Ernst, 2011; Lawn and Zumla, 2011). Recently, we
found that mutations in the zebrafish gene leukotriene A4 hydro-
lase (lta4h),whichcatalyzes theproductionof theproinflammatory
eicosanoid LTB4 (Samuelsson et al., 1987) (Figure 1A), were asso-
ciatedwith hypersusceptibility toMycobacteriummarinum (Tobin
et al., 2010). Functional analyses suggested that reduced LTA4H
activity confers hypersusceptibility via an excess production of
anti-inflammatory lipoxins (Figure 1A) (Bafica et al., 2005; Chen
et al., 2008; Serhan, 2007; Tobin et al., 2010). In humans, two
intronic single nucleotide polymorphisms (SNPs) at the LTA4H
locuswere associatedwith TB (Tobin et al., 2010). Heterozygosity
for the two SNPs was protective, while both homozygous states
corresponded to increased disease severity. These findings
were surprising for two reasons: heterozygous advantage is
unusual, and they implicateboth insufficientandexcessive inflam-
mation in the pathogenesis of TB (Behr et al., 2010; Tobin et al.,
2010). Given the clinical and therapeutic implications of such
a dichotomous, genotype-mediated susceptibility, we sought to
characterize underlying mechanisms of these two susceptible
extremes and to test their relevance in human disease.
In the present study, we use zebrafish larvae to uncover the
biological basis of LTA4H heterozygous advantage. We show
that both excessive proinflammatory and anti-inflammatory-
proresolving eicosanoids, namely LTB4 and LXA4, each promote
bacterial growth by different pathways that converge on the
same endpoint, and identify proof-of-principle genotype-
specific therapies intercepting points along the distinct path-
ways that dominate in the twogenotypes.We identify a functional
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Figure 1. Identification of Eicosanoids in Zebrafish by LC-MS-MS
(A) Lipoxygenase-derived lipid mediator biosynthesis pathway from arachidonic acid and contribution of LTA4H.
(B) LC-MS/MS lipid mediator lipidomics of adult zebrafish. Left: Extracted ion chromatograms of two key lipid mediators, LXA4 metabolite 13,14-dihydro-15-oxo
LXA4 (351- > 115) and LTB4 (335- > 195). Right: MS/MS fragmentation and structure assignment of lipid mediators. For further MS
3 analysis, see Figure S1.
(C) LXA4 metabolite levels (mean ± SEM of three animals) in wild-type (wt) and lta4h mutant zebrafish p = 0.02 (Student’s unpaired t test).
(D) TNF mRNA levels (mean ± SD) in pooled 3 dpi zebrafish larvae analyzed 7 hr after injection with LXA4 or its metabolite 13, 14-dihydro-15-oxo LXA4 identified
using reported criteria (Serhan et al., 1993).
***p < 0.001 (one-way ANOVA with Dunnett’s post hoc test). See also Figure S1.SNP in the human LTA4H promoter, linked to the previously
identified intronic SNPs, that regulates LTA4H transcriptional
activity. We confirm its association with disease severity and
intra-cerebral inflammatory response in meningeal TB and we
show the SNP is associated with response to adjunctive dexa-
methasone treatment, with only individuals with the high-
expression LTA4H genotype deriving benefit from this stan-
dard-of-care anti-inflammatory therapy. Together, these results
suggest that increased disease severity in humans can also
occur for fundamentally opposite reasons: an inadequate host
immune response to infection or an excessive one. Thus, the
ability to tailor therapies to these divergent inflammatory states
and specific LTA4H genotypes could improve patient outcomes.
RESULTS
LTA4H Deficiency Increases Bioactive Lipoxins
Lipoxins can impair immunity to Mycobacterium tuberculosis,
promoting necrotic death of infected macrophages, and inhibit-ing initiation of cell-mediated immunity (Chen et al., 2008; Divan-
gahi et al., 2010). Functional studies in zebrafish larvae had sug-
gested a model wherein reduced LTA4H activity increases
lipoxin levels, which produce hypersusceptibility by inhibiting
transcription of TNF, a key protective cytokine (Figure 1A).
Evidence for excess lipoxin function in LTA4H deficiency was
discernible even at baseline in uninfected larvae (Tobin et al.,
2010). For verification of these functional findings, we used liquid
chromatography tandem–mass spectrometry (LC-MS-MS) to
identify relevant eicosanoid mediators in uninfected wild-type
adult zebrafish and siblings homozygous for an lta4h mutation
(a large retroviral insertion in exon 7 that compromises gene
function) (Tobin et al., 2010). The expected precursors, products
and further metabolites of the lipoxin A4 pathway were identified
and quantified, as well as leukotriene B4 using deuterium labeled
internal standards with LC-MS-MS (Figure 1B and Figures S1A
and S1B, available online). While lipoxin A4 (LXA4) was present
in trace amounts, its further metabolite 13,14-dihydro-15-oxo
LXA4 (Serhan et al., 1993) was abundant, and its levels wereCell 148, 434–446, February 3, 2012 ª2012 Elsevier Inc. 435
increased 2.1-fold (p = 0.02) in lta4hmutants above that in wild-
type (Figures 1B and 1C and Figures S1C–S1E). This LXA4
metabolite displayed functional activity in vivo comparable to
LXA4: injection into M. marinum-infected larvae reduced TNF
transcription 2.6-fold and 2.3-fold (p < 0.05), respectively for
LXA4 and its metabolite (Figure 1D). We also identified the perti-
nent eicosanoids in zebrafish larvae (Figure S1F and S1G), thus
validating our functional analyses of infection outcomes at this
developmental stage (Tobin and Ramakrishnan, 2008; Tobin
et al., 2010). These results identify the conserved eicosanoids
in zebrafish and provide definitive evidence that LTA4H defi-
ciency increases functional lipoxin production.
Excess LXA4 and LTB4 Activity Both Promote
Extracellular Bacterial Growth
Our work in the zebrafish had identified the cellular mecha-
nism whereby LTA4H deficiency produces susceptibility to
M.marinum (Tobin et al., 2010). However, themechanismbehind
the association of human susceptibility with the opposite, high-
LTA4H expression, homozygous genotype was unclear (Behr
et al., 2010; Tobin et al., 2010). So we now used zebrafish larvae
to additionally model the high LTA4H activity human genotype.
To produce an LTA4H excess state, we injected lta4h RNA into
one-cell stage embryos to create what we call LTA4H-high
animals. With wild-type animals serving as surrogates for the
protected heterozygote state, low-activity LTA4H homozygous
genotypes weremodeled using amodified antisense oligonucle-
otide (morpholino) to knock down zebrafish lta4h expression
(referred to as LTA4H-low animals) (Tobin and Ramakrishnan,
2008; Tobin et al., 2010). We established the specificity of the
effects of both the MO and RNA by showing that lta4h sense
but not antisense RNA rescued the increased bacterial burden
of the lta4h morphants (Figure S2). The LTA4H-high animals
displayed evidence of increased LTB4 activity, both chemoat-
tractant and proinflammatory (Figure 1A) (Goldman et al., 1993;
Haeggstrom, 2004; Samuelsson et al., 1987; Tobin et al., 2010).
More phagocytes were recruited toM. marinum infection of their
hindbrain ventricle (1.7-fold increase over wild-type siblings,
p = 0.01), and they expressed 1.5-fold more TNF mRNA than
wild-type (p = 0.02) soon after infection (Figures 2A and 2B).
We next asked if and how their hyperinflammatory state
renders the LTA4H-high fish susceptible to infection. While path-
ological, overexuberant inflammation and immune responses
are recognized to cause clinical exacerbations of TB and
leprosy, these generally occur in the face of effective mycobac-
terial control with chemotherapy (Chambers et al., 1984; Hawkey
et al., 2005; Kahawita and Lockwood, 2008; Markman and
Eagleton, 1981). Therefore these excessive host-detrimental
immune responses are thought to be neutral or even favorable
to bacterial control. However, soon after infection (by 3 days
postinfection (dpi)), the LTA4H-high fish had increased bacterial
burdens over their wild-type siblings (1.6-fold, p < 0.01), similar
to the LTA4H-low fish (Figures 2C and 2D). This result not only
supported the human LTA4H heterozygote advantage model
but, importantly, linked increased inflammation to increased
bacterial growth.
A cellular mechanism by which increased inflammation in-
creases bacterial burdenswas revealed by a temporal dissection436 Cell 148, 434–446, February 3, 2012 ª2012 Elsevier Inc.of infection in LTA4H-high and LTA4H-low siblings. We had
found earlier that LTA4H deficiency, like TNF signaling defi-
ciency, first produces increased bacterial growth within macro-
phages followed by necrotic death of the heavily infectedmacro-
phages (Clay et al., 2008; Tobin et al., 2010). Macrophage lysis
releases the bacteria into their permissive extracellular milieu
where they continue to grow even more exuberantly in corded
mats. This bacterial cording is a reliable and readily discernible
binary phenotype for the extracellular growth that follows upon
macrophage lysis (Clay et al., 2008; Tobin et al., 2010). In contrast
to LTA4H-low animals, their LTA4H-high siblings displayed an
enhanced ability to control intracellular bacterial growth very
early in infection. At 40 hr postinfection (hpi) when LTA4H-low
fish had the expected 1.5-fold (p < 0.001) increase in bacterial
burdens per macrophage over wild-type, their LTA4H-high
siblings restricted intramacrophage bacterial growth even better
than wild-type (1.5-fold reduction over wild-type, p < 0.001) (Fig-
ure 2E). Yet by three to four days, both genotypes had similar
increases in bacterial burdens over wild-type and displayed
extracellular growth as judged by the cording phenotype
(Figures 2F and 2G). To confirm that the bacterial cording
phenotype reflected the lysis of infected macrophages, we
enumerated the number of macrophages after neutral red stain-
ing at 4 dpi (Tobin et al., 2010). The LTA4H-high animals had the
expected depletion of macrophages associated with cording
(2.7-fold fewer than wild-type, p < 0.0001) similar to that seen
in the LTA4H-low animals (3.9-fold fewer than wild-type, p <
0.0001) (Figures 2H and 2I). Thus, despite their increased ability
to curtail bacterial growth, the LTA4H-high macrophages under-
went lysis, releasing bacteria into the extracellular milieu where
their numbers could then reach those of the LTA4H-low fish.
For LTA4H deficiency, we had found it to both be associated
with and to phenocopy TNF deficiency. Given the increased
TNF levels in the LTA4H-high animals, we wondered if TNF
excess, like TNF deficiency, also caused necrotic lysis of the in-
fected macrophages, thereby mediating cording-associated
hypersusceptibility for both genotypes (Vandenabeele et al.,
2010) (Figure 3).
LXA4 and LTB4 Excess Both Produce Susceptibility via
TNF Dysregulation
Ourmodel suggested that opposite deviations in TNF levels from
wild-type drive the hypersusceptibility of LTA4H deficiency and
excess respectively (Figure 3). If so, then wild-type animals
should be rendered hypersusceptible by TNF deviations in either
direction i.e., TNF knockdown or addition of exogenous TNF.
Moreover, TNF excess should phenocopy the unusual infection
phenotype seen for LTA4H-high animals, namely initial improved
control of intracellular macrophage growth followed by cell lysis
and exuberant extracellular bacterial growth with cording. In
order to test this model, we confirmed that recombinant zebra-
fish TNF (Roca et al., 2008) was functional in our system: we
observed a graded reversal of hypersusceptibility of TNF defi-
ciency created by MO knockdown and identified the minimal
dose that reversed it completely (Figure S3). We could now
compare the infection phenotypes of TNF deficiency (TNF-
low) and TNF excess (TNF-high) states by using wild-type
animals injected with either the TNF MO or recombinant TNF.
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Drive Hypersusceptibility in Zebrafish
(A) Median number of macrophages recruited
to the hindbrain ventricle of wild-type and
LTA4H-high siblings 4 hr after injection of 150-200
M. marinum into this space at 30 hpf. p = 0.01
(Student’s unpaired t test). Representative of two
independent experiments.
(B) TNF mRNA levels (mean ± SEM of three
independent experiments) for control and LTA4H-
high siblings 1 dpi with 150-200 M. marinum.
p = 0.02 by Student’s unpaired t test.
(C) Fluorescence images of representative wild-
type, LTA4H-low and LTA4H-high larvae 3 dpi with
90-100 M. marinum.
(D) Bacterial burden of all larvae from (C) by fluo-
rescence pixel counts (FPC). **p < 0.01; ***p <
0.001. (one-way ANOVA with Tukey’s post
hoc test; all other comparisons not significant).
Representative of > 7 independent experiments
measuring differences in bacterial burden of the
three genotypes.
(E) Mean (±SEM) number of bacteria per infected
macrophage in 11 wild-type larvae, 8 LTA4H-low
larvae and 13 LTA4H-high larvae, 40 hpi with
150-200 erpmutantM. marinum. ***p < 0.001 (one
way ANOVA with Dunnett’s post hoc test). Re-
presentative of two independent experiments.
(F) Fluorescence images showing discrete bacte-
rial clumps indicative of macrophage residence in
wild-type versus corded extracellular bacteria in
their LTA4H-low and LTA4H-high siblings at 3 dpi
with 150-200 M. marinum.
(G) Percentage of animals in (F) with cording
among wild-type, LTA4H-low and LTA4H-high
siblings 4 dpi after infection with 90-100
M. marinum. *p < 0.05; ***p < 0.001 (Fisher’s exact
test comparing LTA4H-low and LTA4H-high to
wild-type).
(H) Quantitation of neutral red positive cells 4 dpi
after infection with approximately 100M. marinum
in sibling controls and LTA4H-high animals and (I)
sibling controls and LTA4H-low animals.
See also Figure S2 and Movie S1, Movie S2, and
Movie S3.TNF-low animals gave the expected phenotype similar to the
LTA4H-low animals: diminished control of bacterial growth
within macrophages followed by increased bacterial burdens
accompanied by macrophage lysis and bacterial cordingCell 148, 434–446(Figures 4A–4D) (Tobin et al., 2010). In
contrast, TNF-high animals displayed
the signature phenotype of LTA4H-high
animals: initial improved control of bacte-
rial growth within macrophages was then
followed by increased bacterial burdens
accompanied by macrophage lysis and
cording (Figures 4E–4H). These data
were consistent with the LTA4H-low and
-high phenotypes being due to TNF defi-
ciency and excess, respectively.Next, we asked if deviations in TNF do indeed account for the
susceptibility of the LTA4H-low and –high states. If TNF defi-
ciency is the principal driver of LTA4H-low susceptibility then
it should be corrected by the administration of recombinant, February 3, 2012 ª2012 Elsevier Inc. 437
LTA4H Deficiency
TNF Deficiency
Increased Intramacrophage
Bacterial Growth
TNF Excess
Reduced Intramacrophage
Bacterial Growth
Macrophage Necrosis
Exuberant Extracellular Growth with Cording
LTA4H Excess
LXA4 Excess LTB4 Excess
Figure 3. Model of Proposed Mechanism for Susceptibility of
LTA4H-low and –high Genotypes wherein either TNF Deficiency or
Excess Results in Macrophage Necrosis and Exuberant Extracel-
lular Bacterial GrowthTNF. Both increased bacterial burdens and the accompanying
bacterial cording were rescued by a single dose of recombinant
TNF (Figures 4I and 4J). Conversely, LTA4H-high susceptibility
should be corrected by TNF MO blockade of these animals.
Again the reduction of bacterial burdens with the MO was
accompanied by a reduction in bacterial cording (Figures 4K
and 4L). In sum, both hypersusceptible states are mediated
substantially, if not entirely, by TNF deviations from an optimal
level, in opposite directions for each state. TNF excess, like
TNF deficiency, causes macrophage lysis, placing the bacteria
in a permissive extracellular niche (Figure 3).
Distinct Therapies for Hypersusceptibility from LXA4
and LTB4 Excess
If poor outcomes in TB can arise from extreme inflammatory
states then specific, targeted interventions within these eicosa-
noid pathways should correct the hypersusceptibility associ-
ated with each state while being neutral or even detrimental
to the other state (Figure 5A). We tested this first with two
agents expected to alter lipoxin levels in opposing directions:
reducing lipoxins should benefit the LTA4H-low state while
increasing lipoxins should specifically benefit the LTA4H-high
state by dampening the excessive proinflammatory effects of
LTB4 excess (Figure 5A). To reduce lipoxin levels, we used
a 15-lipoxygenase inhibitor, shown earlier to reduce lipoxin
function in zebrafish larvae (Auerbach et al., 1996; Tobin
et al., 2010). This treatment significantly reduced the infection
burdens of LTA4H low animals (Figure 5B). In contrast, those
of LTA4H-high animals were increased slightly, which was
consistent with the removal of lipoxin-mediated TNF repression
hence elevating their already high TNF levels further (Figures 5A
and 5C). Conversely, we sought to increase endogenous lipoxin
function by stimulating the production of aspirin-triggered
15-epi-LXA4 (Claria and Serhan, 1995) which exerts anti-inflam-
matory effects both on inflammatory cell migration and cytokine
production in humans (Morris et al., 2009). We had shown
earlier that this aspirin triggered product (15-epi-LXA4) is active
in zebrafish larvae where it mimics LXA4 in inhibiting neutrophil
migration (Tobin et al., 2010). Here, we identified a concentration438 Cell 148, 434–446, February 3, 2012 ª2012 Elsevier Inc.of acetylsalicylic acid (ASA), the active ingredient of aspirin,
which similarly inhibits neutrophil migration (Figure S4). ASA
decreased infection in LTA4H-high animals while increasing
it in their LTA4H-low siblings, as would be expected from
a further increase in their endogenous lipoxin excess (Figures
5D and 5E).
We could also specifically overcome the increased bacterial
burdens of LTA4H-high animals by directly blocking LTB4
activity with a pharmacological antagonist of the LTB4 receptor
BLT1 (Figures 5A and 5F). This antagonist did not alter LTA4H-
low bacterial burdens (Figure 5G), a finding consistent with our
model that LTB4 deficiency per se does not increase suscepti-
bility (Tobin et al., 2010).
Finally, for each of the two genotypes we assessed the effect
of dexamethasone, a glucocorticoid used for its broad anti-
inflammatory and immunosuppressive effects in a range of
human diseases including certain serious forms of TB (Mayosi
et al., 2002; Prasad and Singh, 2008) (Figure 5A). Dexametha-
sone gave the expected therapeutic result with LTA4H-high
animals while this same dose rendered LTA4H-low animals
even more susceptible (Figures 5H and 5I).
We tested further the specificity of these therapeutic effects
in two ways. That the efficacy of the compounds was specific
to the appropriate LTA4H genotype was further validated
by assessing their effects on wild-type animals in which
none had a salutary effect at these concentrations (Figures
S5A–S5D). Second, our model would suggest that therapies
specific to the LTA4H-low and LTA4H-high states work by cor-
recting the respective TNF deviations from wild-type. The 15-
lipoxygenase inhibitor must work by increasing TNF in the
LTA4H deficient state whereas ASA, the LTB4 receptor antag-
onist and dexamethasone must work by reducing TNF in the
LTA4H excess state. If so, then the therapeutic effect of the
15-lipoxygenase inhibitor should be abrogated by the TNF
morpholino, and the efficacy of the other compounds abro-
gated by the addition of TNF. These predictions were borne
out for all four compounds (Figures S5E–S5H). Together, these
results provide proof-of-principle for genotype-directed inter-
ventions targeting pro- and anti-inflammatory lipoxygenase
mediator pathways that in turn influence TNF levels, and for
their effects in the zebrafish. The genotype-dependent efficacy
of dexamethasone therapy in the zebrafish suggests that
genotype may also influence the efficacy of this therapy in
human TB.
A Polymorphism in the Human LTA4H Promoter
Regulates Transcriptional Levels
In order to test these therapeutic principles in the context of
human disease, we explored the regulation of LTA4H in humans.
Previously we identified intronic SNPs of LTA4H that are associ-
ated with incidence, severity, and survival in TB or leprosy (Tobin
et al., 2010). These intronic SNPs were unlikely to directly
mediate differences in gene expression or activity. In order to
identify potential functional polymorphisms, we identified all
variants in the LTA4H locus that had become accessible through
the 1000 Genomes Project (Durbin et al., 2010). One such SNP,
rs17525495 C/T, lies 12 nucleotides upstream of the LTA4H
transcription start site at chr12:96,429,377 (hg19). The frequency
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Figure 4. Modulation of TNF Levels Results in Genotype-Specific Rescue of LTA4H-Mediated Hypersusceptibility
(A) Mean (±SEM) number of bacteria per infected macrophage 40-44 hpi with 150-200 erp mutant M. marinum of wild-type or TNF morphant (MO) siblings.
(B) FPC in control or tnf morphant siblings 3 dpi with 90-100 M. marinum.
(C) Quantitation of frequency of bacterial cording of the animals in (B).
(D) Quantitation of neutral red positive cells 4 dpi after infection with 100 M. marinum in sibling controls or tnf morphants.
(E) Mean (±SEM) number of bacteria per infected macrophage at 40-44 hpi in wild-type animals with or without injection of 0.5 ng rTNF 12 hr after infection with
150-200 erp mutant M. marinum.
(F) FPC in control or rTNF injected siblings 3 dpi with 90-100 M. marinum.
(G) Quantitation of frequency of bacterial cording of the animals in (F).
(H) Quantitation of neutral red positive cells at 4 dpi after infection with 90-100 M. marinum in sibling controls or rTNF injected animals.
(I) FPC in wild-type or lta4h morphant siblings 3 dpi with 90-100 M. marinum per animal after injection of 0.5 ng rTNF at 12 hpi.
(J) Bacterial cording frequency of the animals in (I).
(K) FPC in wild-type animals, LTA4H-high siblings, and LTA4H-high plus TNF morphant animals, at 3 dpi with 90-100 M. marinum.
(L) Quantitation of frequency of bacterial cording in the animals in (K).
Statistical comparisons in panels (I) and (K) by one-way ANOVA with Tukey’s post hoc test; in panels (C),(G),(J) and (L) by Fisher’s exact test; (A),(B),(D),(E),(F),(H)
by Student’s unpaired t test. For all panels *p < 0.05; **p < 0.01; ***p < 0.001, all other comparisons not significant. See also Figure S3.of allele T of rs17525495 has an unusual worldwide distribution:
highest in Asian populations (0.29), intermediate in African pop-
ulations (0.12) and least common in European populations (0.04)
(www.genome.ucsc.edu). Four lines of evidence suggest that
rs17525495 genotype influences LTA4H transcription. First,
expression profiles of lymphoblastoid cell lines (LCLs) from the
International HapMap project (Stranger et al., 2007) indicate
that LTA4H mRNA levels differ by rs17525495 genotype, with
higher activity associated with the rarer T allele (Figure 6A andFigure S6A). Second, we showed using LCLs from healthy
controls that these mRNA differences were reflected in differ-
ences in LTA4H protein levels. rs17525495 TT is associated
with 2.3-fold higher LTA4H protein expression than CC, with
intermediate expression in the CT cell lines (p = 0.0002) (Fig-
ure 6B and Figure S6B). Third, to control for differences in
genetic background outside of this locus and examine transcrip-
tion directly, we isolated mRNA from LCL GM19190, which is
heterozygous both at rs17525495 and at a rare coding sequenceCell 148, 434–446, February 3, 2012 ª2012 Elsevier Inc. 439
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Figure 6. The Human LTA4H Promoter Variant
rs17525495 C/T Is Associated with Differences in
LTA4H RNA and Protein Expression
(A) LTA4H mRNA expression in lymphoblastoid cell lines
(LCLs) from Asian individuals (CHB+JPT) (from (Stranger
et al., 2007)) p = 0.026 (one-way ANOVA). Data for all
HapMap samples shown in Figure S6A.
(B) LTA4H protein expression levels from LCLs of
unrelated Han Chinese CC or TT homozygotes or CT
heterozygotes, detected by Western blot and normalized
to b-tubulin (also see Figure S6B). p = 0.0002 (Student’s t
test). Representative of 2 independent experiments for
the CC and TT homozygotes; CT heterozygotes were
analyzed once in this experiment.
(C) Number of cDNA clones corresponding to the C or T
allele at rs17525495 isolated from the heterozygous LCL
GM19190.
(D) Luciferase expression (mean ± SEM of 11 independent
experiments) transcribed from a one kb promoter frag-
ment immediately upstream of the LTA4H translation start
site containing the rs17525495 C and T alleles. p = 0.0064
for uninfected cells and p = 0.02 for M. marinum-infected
cells (paired t test).
See also Figure S6.SNP (rs79510571), which served as a tag to discriminate
between transcripts. Transcripts of rs79510571 T were twice
as abundant as transcripts of allele C (p = 0.03) (Figure 6C).
Fourth, as an independent test of whether these associations
were due directly to the effect of rs17525495 alleles, we cloned
one kb of each of the two promoter genotypes into a luciferase
expression vector and transfected each into the murine macro-
phage cell line RAW264.7. The promoter with rs17525495 T
produced 1.3-fold higher luciferase activity than the promoter
with genotype C (p = 0.006), an increase that was maintained
after M. marinum infection of the macrophages (1.2-fold, p =
0.02) (Figure 6D). The promoter with rs17525495 T produced
a similarly higher luciferase activity than the promoter with geno-
type C in the human macrophage THP-1 cell line (Figure S6C).
Together these data indicate that the LTA4H promoter polymor-
phism influences the level of transcription in macrophages,
a cell type central to the fate of mycobacterial infection, andFigure 5. Genotype-dependent Therapies Rescue Hypersusceptibility
(A) Pathways of LTB4 and LXA4 synthesis highlighting points of pharmacological
(B) FPC of LTA4H-low or wild-type siblings in the presence or absence of 100
2 independent experiments.
(C) FPC as in (B) for LTA4H-high animals or wild-type siblings. Representative of
(D) FPC of LTA4H-high or wild-type siblings in the presence or absence of 1 mM
(E) FPC as in (D) of LTA4H-low or wild-type siblings.
(F) FPC of LTA4H-high or wild-type siblings in the presence or absence of 1 mMof
of 3 independent experiments.
(G) FPC as in (F) for LTA4H-low or wild-type siblings.
(H) FPC of LTA4H-high and wild-type siblings in the presence or absence of 0.75
(I) FPC as in (H) for LTA4H-low animals or wild-type siblings. Representative of
analyses performed at 3 dpi.
Statistical comparisons in all panels by one-way ANOVA with Tukey’s post hoc tparticularly so in our proposed model of hypersusceptibility
(Figure 3).
The LTA4H Promoter Polymorphism Is Associated with
Treatment Response in TB Meningitis
In the zebrafish, the two inflammatory poles determined by alter-
nate lta4h genotypes can be distinguished by their responses to
targeted pharmacotherapies. We tested whether the human
LTA4H polymorphism regulating transcriptional levels also influ-
ences response to therapy among patients with TB meningitis.
The most severe form of TB, TB meningitis kills or disables
more than half of sufferers despite effective antimicrobial
chemotherapy (Prasad and Singh, 2008; Schoeman et al.,
1997; Thwaites et al., 2004). Adjunctive anti-inflammatory
therapy with glucocorticoids became the standard of care after
several clinical trials worldwide suggested that glucocorticoids
induce a modest reduction in morbidity and mortality (Prasadto M. marinum in the Zebrafish
intervention.
nM of PD146176, a 15-lipoxygenase inhibitor (15-LOXi). Representative of
2 independent experiments.
ASA. Representative of 2 independent experiments.
U75302, an antagonist of the BLT1 LTB4 receptor (LTB4-R ant). Representative
mM DEX. Representative of 3 independent experiments.
2 independent experiments. 150-200 M. marinum used for all infections with
est. *p < 0.05; **,p < 0.01; ***p < 0.001. See also Figure S4 and Figure S5.
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Figure 7. rs17525495 Genotype Influences TB Meningitis Survival, Inflammation, and Treatment Response
(A) Mortality from TB meningitis for all patients (treated and untreated with dexamethasone (DEX)), stratified by rs17525495 genotype (p = 0.02, log rank test).
(B) Median pre-treatment leukocyte counts in cerebrospinal fluid stratified by rs17525495 genotype (p = 0.006, one-way ANOVA).
(C) Influence of adjunctive dexamethasone treatment on patient survival for all genotypes. Treatment effect is not significant (p = 0.2).
(D) Survival among patients not treated with dexamethasone, stratified by rs17525495 genotype (p = 0.042, log rank test) (E) Survival among patients treated with
dexamethasone, stratified by rs17525495 genotype (p = 0.005, log rank test).
See also Figure S7 and Table S1 and Table S2.and Singh, 2008; Schoeman et al., 1997; Thwaites et al., 2004).
Results of the studies of glucocorticoids for treatment of TB
meningitis present two conundrums (Donald and Schoeman,
2004; Schoeman et al., 1997). First, it is uncertain why the bene-
ficial effects of glucocorticoids are relatively modest. Second,
the mechanisms by which glucocorticoids exert their benefit
are unclear; improved survival is not associated with a significant
reduction in intracranial pressure, or cerebral vasculitis, which
would have been expected to be at the root of the general
anti-inflammatory effects of glucocorticoids (Donald and Schoe-
man, 2004; Schoeman et al., 1997).
Our model addresses these conundrums. Based on our
model, we predict that (i) the individuals most severely affected
with TB meningitis have opposite inflammatory states governed
by their LTA4H genotype and (ii) only patients from the hyperin-
flammatory pole benefit from glucocorticoids. We tested these
predictions in 182 Vietnamese patients with TB meningitis
who participated in prior clinical studies in Ho Chi Minh City
(Table S1). With respect to our first prediction, individuals with
the highest mortality from TB meningitis were homozygous at
rs17525495 (Figure 7A). This result was expected, given our
previous analysis with the linked intronic SNPs of LTA4H (Tobin
et al., 2010) (Figure S7). As an assessment of these patients’
inflammatory state, we evaluated leukocyte counts in cerebro-
spinal fluid (CSF) samples that were obtained for the diagnosis
of TB meningitis prior to initiating treatment. CSF leukocyte442 Cell 148, 434–446, February 3, 2012 ª2012 Elsevier Inc.counts in heterozygotes were intermediate between those of
the homozygous genotypes (Figure 7B). High leukocyte counts
in human TT patients mirrored the increased numbers of leuko-
cytes in the hindbrain ventricle of LTA4H-high zebrafish during
infection (Figure 2A). In contrast to these differences in cell
migration, which is known to be affected by leukotrienes and
lipoxins (Figure 1A), nonspecific inflammatory parameters such
as CSF opening pressure indicative of intracranial pressure
were not associated with rs17525495 genotype (Table S2).
Our results suggested that the LTA4H promoter variant influ-
ences meningitis outcome and a specific inflammatory marker
among the Vietnamese patients, but not in the same way for
the two parameters. How can the survival advantage of CT
heterozygotes be reconciled with their intermediate white cell
counts?
To address this question, we tested the second prediction
of our model, that the marginal response to dexamethasone
among these TB meningitis patients generally (Figure 7C) rep-
resented an LTA4H genotype-dependent response, as we had
seen in the zebrafish (Figures 5F and 5G). That is, does the
effect of dexamethasone depend on a patient’s genotype at
rs17525495? Among patients not treated with dexametha-
sone, those with rs17525495 TT genotype had the highest
mortality (Figure 7D). In contrast, among patients treated
with dexamethasone, those with genotype rs17525495 TT had
the lowest mortality (Figure 7E). These relationships were
not due to any interaction between pre-treatment disease
severity and genotype (Table S2). These results suggest that
LTA4H genotype has a critical influence on response to
standard-of-care adjunctive anti-inflammatory therapy in TB
meningitis.
DISCUSSION
Our iterative dual approaches in zebrafish and humans lead us to
conclude that TB is not only a disease of failed immunity. People
succumb for the opposite reasons of an inadequate or excessive
immune response. Virulent mycobacteria themselves have
evolved to disrupt the fine balance of pro- and anti-inflammatory
cues required for host protection (Desvignes and Ernst, 2009;
Volkman et al., 2010). Distinct virulence determinants can
manipulate macrophage inflammation toward both extremes,
inducing anti-inflammatory lipoxin production but also pro-
moting proinflammatory TNF (Agarwal et al., 2009; Chen et al.,
2008). The host genetic differences in immunoregulation we
identify are overlaid on mycobacterial immunomodulation so
as to dramatically tilt this balance.
Genetic differences in LTA4H transcription affect inflamma-
tory response, outcome and response to therapy in TB menin-
gitis. The functional promoter variant that causes this differential
LTA4H transcription is common in much of the world where TB
is endemic, but intriguingly is much less common in Europe. A
recent study of TB in a Russian cohort failed to find an associa-
tion of susceptibility to TB with other polymorphisms at this
locus (Curtis et al., 2011). We speculate that the difference
between the negative results for the Russian cohort and the
positive association that we observed between the functional
promoter variant and disease severity for TB in a Vietnamese
cohort may be due either to differences in linkage disequilibrium
between the functional promoter variant and the other LTA4H
SNPs in the Russian cohort compared to Asian cohorts (linkage
disequilibrium among the variants is shown for the Vietnamese
cohort in Figure S7) and/or to differences in the influence of
the functional promoter variant on susceptibility to TB per se
versus its influence on severity of disease among infected indi-
viduals. In this context, it is noteworthy that LTA4H-mediated
differences in disease severity and treatment response that
are manifested within hours of infection in the zebrafish larval
model are also evident in advanced manifestations of human
disease, i.e., TB meningitis. The ability of macrophages to
contain mycobacterial infection is critical throughout infection,
and this ability is dependent on finely tuned LTA4H levels. In
addition, because lipoxins and leukotrienes may also impact
lymphocyte differentiation (Divangahi et al., 2010; Payan et al.,
1984), LTA4H genotype-mediated differences are probably
further amplified during later stages of TB when adaptive immu-
nity is in play.
If people succumb to TB for two fundamentally different
reasons then it is imperative to design therapeutic strategies
that reflect this dichotomy. In evaluating the effects of dexa-
methasone treatment for TB meningitis without taking into
account host genotype, the very substantial benefit of dexa-
methasone for patients with the high-activity genotype may
be diluted by its neutral to possibly detrimental effect for indi-viduals with the low-activity genotype. In this disease with
extremely high mortality, a simple genotyping assay for the
presence of the high-activity allele could provide a rapid and
inexpensive approach to direct adjunctive therapy to the indi-
viduals it would benefit. Therefore, clinical studies are urgently
needed to determine if genotype-mediated dexamethasone
responsiveness is a feature of TB meningitis in other parts of
the world. In particular, we need to assess whether or not
adjunctive dexamethasone harms those patients with the CC
genotype, for this would have important implications for clinical
practice and suggest alternative treatment strategies for this
group.
Adjunctive therapies tailored to LTA4H genotype may
improve outcomes for other forms of TB. This work shows
that dexamethasone exerts its benefit by intercepting mecha-
nisms fundamental to mycobacterial pathogenesis itself and
not solely as a general suppressor of host immune responses
gone awry. Thus, glucocorticoids should be therapeutic for
other forms of TB as well. In TB pericarditis, another serious
disease manifestation, adjunctive glucocorticoids are widely
used, but again produce only a modest reduction in mortality
and morbidity (Mayosi et al., 2002). In pulmonary TB, the
most common form of the disease, some studies have re-
ported that adjunctive glucocorticoids induce faster clearance
of bacteria from the sputum, whereas others have failed to
find a beneficial effect (Muthuswamy et al., 1995). A recent
study in HIV-positive patients found improved bacterial
clearing with adjunctive glucocorticoid treatment that was
associated with a reduction in TNF levels (Mayanja-Kizza
et al., 2005). Therefore, glucocorticoids may improve out-
come in all forms of TB associated with high LTA4H activity.
In addition, anti-TNF therapies have been reported to accel-
erate the bacteriological response in pulmonary TB patients
(Wallis, 2005). We speculate that the observed modest
beneficial effects of these adjunctive, therapies in the gen-
eral patient pool may in fact represent their substantial benefit
in the LTA4H-high genotype, as we have found for TB
meningitis.
Glucocorticoids are broadly acting drugs with serious side
effects. Our work suggests that direct manipulation of eicosa-
noid lipoxygenase pathways may provide better targeted thera-
pies. For high-activity genotypes these may include therapies
that more directly target LTB4 excess, as exemplified by the
beneficial effect of LTB4 receptor blockade in the zebrafish.
Other therapies for the high-activity genotype that target eicos-
anoid balance may also prove effective. Aspirin is one of the
most widely used, well-tolerated and inexpensive drugs in
history, and one of its important effects is to trigger 15-epi-
LXA4 (Claria and Serhan, 1995; Morris et al., 2009; Serhan
et al., 2010), which in turn can inhibit TNF (Ariel et al., 2003).
In the zebrafish, we have found genotype-dependent rescue
by the active ingredient of aspirin, a result that is supported
by two preliminary human clinical trials in TB meningitis (Misra
et al., 2010; Schoeman et al., 2011). In particular, the clinical trial
reporting that aspirin may improve outcome from TB meningitis
comparably and additively to that induced by glucocorticoids
(Misra et al., 2010), is consistent with the synergistic effect of
the two compounds predicted by our model. It would beCell 148, 434–446, February 3, 2012 ª2012 Elsevier Inc. 443
intriguing to evaluate aspirin-responsiveness by genotype.
Finally, our data suggesting that TNF excess caused by the
LTA4H-high genotype plays a prinicipal role in pathogenesis,
makes it important to understand this pathway deeply. In partic-
ular, it would be important to identify the cellular sources of TNF
that contribute to pathology and the mechanism by which
excess TNF produces necrosis of infected cells. Such an under-
standing may make it possible to tap into drugs that are being
developed for the treatment of programmed necrosis in the
context of other diseases (Christofferson and Yuan, 2010).
Then, for treatment of the low-activity LTA4H genotypes, the
development of agents that limit excessive lipoxin production
and boost inflammation should improve outcome, as we have
uncovered here in the zebrafish.
The basic innate inflammatory pathways affected by this gene
are central to many infections. The genotype-directed TB treat-
ment strategies suggested by this work may find use in other
serious infections.EXPERIMENTAL PROCEDURES
Bacterial Strains, Embryo Infection, and Husbandry
These were used and performed as described in (Tobin et al., 2010).
Eicosanoid Extraction and LC-MS-MS Lipid Mediator Lipidomics
Adult zebrafish from an incross of lta4hzm5961/+ heterozygotes were
identified by PCR as in (Tobin et al., 2010), and samples were extracted and
analyzed as described in Extended Experimental Procedures in the Supple-
mental Information.
Quantitative RT-PCR
This was performed as described in (Tobin et al., 2010) and in Extended Exper-
imental Procedures in the Supplemental Information.
Morpholino and RNA Injections
Morpholinos were obtained from Genetools (Eugene, OR) and injections were
performed as described in (Tobin et al., 2010) in Extended Experimental
Procedures in the Supplemental Information.
Recombinant TNF microinjection
Vehicle, 0.5 ng or 1.0 ng of recombinant zebrafish TNF (Roca et al., 2008)
was microinjected into the caudal vein of each animal at 16 hpi.
Pharmacological Interventions in Zebrafish
After infection, small molecules were applied via soaking. Solutions were
changed daily. All conditions and controls were standardized to a final
concentration of 0.5% DMSO. PD 146176 (BIOMOL) was applied at a final
concentration of 100 nM16 hpi. U75302 (BIOMOL) was applied at a concentra-
tion of 1 mM directly after infection. Dexamethasone (Sigma) was applied at
a concentration of 0.75 mM directly after infection. Acetylsalicylic acid (Sigma)
was applied at a concentration of 1 mM.
A single dose of approximately 5 nL of Lipoxin A4 or its metabolite
13,14-dihydro-15-oxo-LXA4 or vehicle control was microinjected into 3
dpi animals (30 for each condition) at a concentration of 0.2 ng/mL in 10%
ethanol. Seven hours later, animals were harvested to measure TNF mRNA
levels.
Microscopy
Microscopywas performed on aNikon E600 equippedwithDIC optics, aNikon
D-FL-E fluorescence unit with 100W Mercury lamp and MFC-1000 z-step
controller (Applied Scientific Instrumentation) or, for whole animal images,
a motorized Nikon inverted Ti-E microscope with further details provided in
the Extended Experimental Procedures.444 Cell 148, 434–446, February 3, 2012 ª2012 Elsevier Inc.Quantitation of LTA4H protein levels
Western blots from Lymphoblastoid cell lines (LCLs) from Han Chinese in the
HapMap project were were probed first with anti-LTA4H (Santa Cruz Biotech-
nology, 1:50 dilution) and then with anti-b-tubulin (Developmental Studies
Hybridoma Bank 1:500) and analyzed as described in Extended Experimental
Procedures.
LTA4H Promoter Luciferase Assays
Transfections were performed on RAW 264.7 macrophages using the Amaxa
nucleofection system and the ratio of luc2 luciferase activity to Renilla
luciferase determined at 18 hr posttransfection. Details of constructs used
are in Extended Experimental Procedures
Clinical Methods
Clinical methods are detailed in Extended Experimental Procedures. All
protocols were performed in accordance with human subjects review com-
mittees at each site, the Oxford Tropical Research Ethics Committee, the
University of Washington (Seattle, WA), and the Western Institutional Review
Board (Olympia, WA).
Genomic DNA was prepared via the QIAamp DNA blood kit (QIAGEN)
from peripheral blood samples. Genotype at rs17525495 was determined
after PCR amplification of a 280 bp fragment containing the SNP of interest
followed by QIAGEN spin column purification and sequencing.
Statistical Analysis
Statistical analysis was performedwith Prism (Graphpad Software) and STATA
(Statacorp LP, Texas, USA) and is detailed in each figure legend.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, two
tables, threemovies, and seven figures and can be foundwith this article online
at doi:10.1016/j.cell.2011.12.023.
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